Successful Treatment of Psoriasis Combined with Bullous Pemphigoid with Dupilumab: A Case Report

被引:4
|
作者
Liu, Jing-Hua [1 ,2 ]
Gao, Qian [1 ]
Ma, Wen-Yi [1 ]
Cheng, Zi-Lin [1 ]
Luo, Na-Na [1 ]
Hao, Ping-Sheng [1 ,3 ]
机构
[1] Hosp Chengdu Univ Tradit Chinese Med, Dept Dermatol, Chengdu, Sichuan, Peoples R China
[2] Dalian Dermatosis Hosp, Dalian, Liaoning, Peoples R China
[3] Hosp Chengdu Univ Tradit Chinese Med, 39 Shi er qiao Rd, Chengdu, Sichuan Provinc, Peoples R China
来源
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY | 2023年 / 16卷
关键词
autoimmune bullous diseases; dupilumab; biologics; comorbidity; Chinese herbal compounds; USTEKINUMAB; THERAPY; PATIENT;
D O I
10.2147/CCID.S415019
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriasis is an immune-mediated chronic inflammatory disease that can be combined with complications such as diabetes, cardiovascular disease, obesity, and kidney disease. The comorbidity of psoriasis with autoimmune bullous diseases (AIBD) has been reported previously in several cases, the most frequent of which is bullous pemphigoid (BP). The underlying mechanisms of psoriasis with BP are not clear and there are no uniform treatment criteria. Based on previous case reports, the coexistence of psoriasis and BP may be related to inflammatory activity, medications, phototherapy, and infection. We report a case of a psoriasis patient who developed BP after taking Chinese herbal compounds and was successfully treated with dupilumab, which is the first reported case of applying dupilumab to treat psoriasis with BP comorbidities.
引用
收藏
页码:1583 / 1587
页数:5
相关论文
共 50 条
  • [1] Case report: Dupilumab for the treatment of bullous pemphigoid
    Wang, Mengxin
    Wang, Juan
    Shi, Bingjun
    DERMATOLOGIC THERAPY, 2022, 35 (07)
  • [2] Use of dupilumab for recalcitrant bullous pemphigoid: A case report
    Lamb, Jillian
    Purdy, Kerri
    Sutherland, Ashley
    SAGE OPEN MEDICAL CASE REPORTS, 2024, 12
  • [3] Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report
    Pop, Samantha R.
    Strock, Daniel
    Smith, Robert J.
    DERMATOLOGIC THERAPY, 2022, 35 (08)
  • [4] Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review
    Granados-Betancort, Elena
    Sanchez-Diaz, Manuel
    Munoz-Barba, Daniel
    Arias-Santiago, Salvador
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
  • [5] Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review
    Cao, Peng
    Xu, Wenjing
    Zhang, Litao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab
    Savoldy, Michelle A.
    Tadicherla, Teja
    Moureiden, Zade
    Ayoubi, Noura
    Baldwin, Brooke T.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (10)
  • [7] Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
    Jafari, S. Morteza Seyed
    Feldmeyer, Laurence
    Bossart, Simon
    Simon, Dagmar
    Schlapbach, Christoph
    Borradori, Luca
    FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [8] The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China
    Wang, Qi
    Xia, Rushan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 118
  • [9] Bullous Pemphigoid Associated with Erythrodermic Psoriasis: A Case Report
    Chen, Wenjuan
    Peng, Chen
    Zheng, Jianfeng
    Lu, Xiya
    Ding, Yangfeng
    Su, Lina
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2022, 15 : 1805 - 1808
  • [10] Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid
    Liang, Guirong
    Qian, Hua
    Sun, Chao
    Zhang, Hanmei
    Li, Zhiliang
    Li, Suo
    Jing, Ke
    Zhao, Chenjing
    Wang, Yuan
    Xiang, Ruiyu
    Li, Xiaoguang
    Feng, Suying
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2025, 100 (02) : 243 - 252